The global nuclear medicine market size was valued at USD 19.55 billion in 2025 and is projected to grow from USD 21.59 billion in 2026 to USD 47.82 billion by 2034, registering a CAGR of 10.45% during the forecast period from 2026 to 2034. North America dominated the nuclear medicine market with a market share of 40.6% in 2025.
The nuclear medicine market is evolving through the growing integration of precision diagnostics and targeted radionuclide therapies, reshaping clinical pathways across oncology, cardiology, and neurology. Increasing adoption of PET-based imaging and novel radiotracers is enhancing early disease detection and treatment monitoring. The market is influenced by advancements in isotope production technologies and the expansion of decentralized radio pharmacy models, improving accessibility in emerging regions. Regulatory emphasis on radiation safety and complex supply chains continues to pose operational challenges. Strategic collaborations between nuclear facilities and biopharmaceutical companies are accelerating innovation. Rising demand for personalized medicine and theranostics is expected to drive sustained market expansion globally.
Download a Free Sample To learn more about this report,
Increasing Adoption of Theranostics in Precision Oncology
Theranostics is becoming increasingly important in nuclear medicine by combining molecular imaging with targeted radionuclide therapy within a coordinated treatment pathway. This approach enables clinicians to identify suitable patients, assess disease characteristics, monitor treatment response, and deliver radiation more selectively to targeted tissues. Growing development of radioligand therapies and targeted alpha and beta emitters is expanding the role of nuclear medicine from disease diagnosis toward personalized treatment.
Growing Use of PET and SPECT Imaging for Precision Disease Detection
PET and SPECT imaging are gaining broader adoption because they provide functional and molecular information that complements conventional anatomical imaging. Advances in radiotracers are improving the ability to detect tumors, cardiovascular abnormalities, neurological disorders, and other conditions at earlier stages. The development of new tracers and hybrid imaging technologies is further expanding clinical applications and increasing demand for nuclear imaging procedures.
Rising Demand for Precision Diagnostics and Targeted Therapies Supports Nuclear Medicine Market Growth
The increasing prevalence of cancer, cardiovascular diseases, neurological disorders, and other chronic conditions is creating demand for more precise diagnostic and treatment approaches. Nuclear medicine can identify biological and molecular characteristics of disease while targeted radiopharmaceutical therapies can deliver therapeutic radiation to specific disease sites. This combination of accurate diagnosis and personalized treatment is strengthening adoption across hospitals, diagnostic centers, and specialized treatment facilities.
High Radiopharmaceutical Production and Infrastructure Costs Can Limit Market Expansion
Nuclear medicine requires specialized radiopharmaceutical manufacturing, isotope production facilities, radiation-controlled environments, specialized imaging equipment, and trained personnel. Short radioisotope half-lives also require coordinated production, quality control, transportation, and administration within strict time windows. These requirements increase operating costs and can limit adoption in healthcare systems where specialized infrastructure and financial resources are constrained.
Expansion of Radiopharmaceutical Therapies Across Oncology Creates New Growth Opportunities
The development of radiopharmaceutical therapies is creating opportunities to expand nuclear medicine beyond conventional diagnostic imaging. Targeted radionuclides can deliver therapeutic radiation to cancer cells while limiting exposure to surrounding healthy tissue, supporting treatment strategies for cancers with specific molecular targets. Increasing clinical development of lutetium-177, actinium-225, and other therapeutic isotopes is creating opportunities for new treatment applications and broader adoption of precision oncology.
Radioisotope Supply Constraints and Complex Distribution Requirements Create Market Challenges
The availability of nuclear medicine procedures depends on reliable access to medical radioisotopes, specialized production facilities, radiopharmacies, and time-sensitive distribution networks. Reactor and cyclotron capacity constraints, production disruptions, transportation requirements, and the short half-lives of certain isotopes can create supply risks. Expanding nuclear medicine therefore requires greater production capacity, diversified isotope sources, and coordinated logistics to maintain consistent availability of diagnostic and therapeutic radiopharmaceuticals.
Lu-177 Segment is Projected to Register the Fastest Growth at a CAGR of 16.4%
The Lu-177 segment is projected to register the fastest growth at a CAGR of 16.4% during 2026–2034. In 2025, the segment accounted for 7.1% of the global nuclear medicine market, with a value of USD 1.39 billion. Growth is driven by increasing adoption of targeted radionuclide therapies, expanding regulatory approvals for Lu-177-based treatments, and rising demand for precision oncology. Ongoing advancements in radiopharmaceutical development and growing investments in personalized medicine are expected to further accelerate segment growth.
The diagnostics segment dominated the market owing to its extensive use in disease detection, functional imaging, and early diagnosis across oncology, cardiology, and neurology. Within diagnostics, SPECT maintained a significant market presence due to the widespread use of Tc-99m and other established radiotracers, while PET continued to witness strong growth driven by increasing adoption of F-18 and next-generation tracers such as PYLARIFY and Illuccix for advanced molecular imaging. The therapeutics segment is expanding steadily as targeted radiopharmaceutical therapies gain broader acceptance for treating various cancers and chronic diseases.
Within therapeutics, alpha emitters are gaining traction because of their highly targeted treatment capabilities and growing clinical adoption in oncology, while beta emitters remain widely used for treating thyroid disorders, neuroendocrine tumors, and metastatic cancers. Brachytherapy continues to maintain stable demand owing to its effectiveness in delivering localized radiation for prostate, cervical, and other cancers, supported by ongoing technological advancements in radioactive seed implantation.
Request Customizationto receive a tailored report.
Oncology Segment is Projected to Register the Fastest Growth at a CAGR of 13.8%
The oncology segment is projected to register the fastest growth at a CAGR of 13.8% during 2026–2034. In 2025, the segment accounted for 25.7% of the global nuclear medicine market, with a value of USD 5.02 billion. Growth is driven by the increasing incidence of cancer, expanding use of molecular imaging, and rising adoption of targeted radiopharmaceutical therapies for diagnosis and treatment. Continuous innovation in precision medicine and theranostic approaches is expected to further strengthen the segment's growth.
The cardiology segment maintained a significant market presence due to the extensive use of SPECT and PET imaging for myocardial perfusion assessment and the diagnosis of cardiovascular diseases. The therapeutic applications segment continues to witness robust growth as targeted radionuclide therapies become increasingly integrated into clinical practice. The neurology segment is expanding steadily with rising demand for advanced imaging techniques to diagnose Alzheimer's disease, Parkinson's disease, and other neurological disorders. The thyroid segment remains an important application area owing to the widespread use of radioisotopes for thyroid imaging and treatment.
The lymphoma, bone metastasis, and endocrine tumor segments are gaining traction as nuclear medicine enables accurate disease staging, treatment planning, and therapy monitoring across various cancers. The pulmonary scans segment continues to support the diagnosis of respiratory disorders, while the urology segment is witnessing increasing adoption of advanced radiotracers for prostate and renal imaging. The other applications segment includes emerging clinical uses that continue to expand with ongoing radiopharmaceutical innovation.
Diagnostic Centers Segment is Projected to Register the Fastest Growth at a CAGR of 12.3%
The diagnostic centers segment is projected to register the fastest growth at a CAGR of 12.3% during 2026–2034. In 2025, the segment accounted for 32.8% of the global nuclear medicine market, with a value of USD 6.41 billion. Growth is driven by increasing demand for specialized molecular imaging services, expanding access to PET and SPECT technologies, and rising preference for outpatient diagnostic procedures. Continued investments in advanced imaging infrastructure are expected to further support segment growth.
The hospitals segment dominated the market owing to their comprehensive diagnostic and therapeutic capabilities, availability of advanced nuclear imaging equipment, and integrated multidisciplinary care for complex diseases. The others segment includes research institutes, specialty clinics, and academic medical centers that continue to contribute to market growth through clinical research, radiopharmaceutical development, and specialized nuclear medicine services.
Speak to an Analystto discuss market opportunities.
North America nuclear medicine market accounted for 40.6% of the global market, reaching USD 7.94 billion in 2025, and is projected to grow at a CAGR of 10.9% during the forecast period. The market is driven by the increasing prevalence of cancer and cardiovascular diseases, growing adoption of molecular imaging technologies, expanding use of radiopharmaceuticals, and strong healthcare infrastructure. Continuous investments in nuclear imaging and targeted radionuclide therapies further support regional market growth.
The US market was valued at USD 6.75 billion in 2025, making it the largest contributor in North America. Rising demand for PET and SPECT imaging, increasing adoption of targeted radiopharmaceutical therapies, expanding healthcare expenditure, and continuous technological advancements continue to drive market growth.
Canada's market reached USD 1.19 billion in 2025. Increasing investments in diagnostic imaging infrastructure, expanding availability of radiopharmaceuticals, growing prevalence of chronic diseases, and rising adoption of precision medicine continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe nuclear medicine market accounted for 28.4% of the global market, reaching USD 5.55 billion in 2025, and is projected to grow at a CAGR of 12.8% during the forecast period. Rising adoption of advanced diagnostic imaging technologies, increasing demand for targeted radionuclide therapies, favorable healthcare policies, and expanding research in radiopharmaceuticals continue to strengthen regional market growth.
The UK market was valued at USD 1.11 billion in 2025. Growing investments in molecular imaging, increasing use of precision diagnostics, expanding nuclear medicine infrastructure, and rising demand for advanced cancer therapies continue to support market growth.
Germany market accounted for USD 1.55 billion in 2025. Strong medical imaging capabilities, increasing clinical research activities, expanding adoption of radiopharmaceuticals, and advanced healthcare infrastructure continue to drive market expansion.
Asia Pacific nuclear medicine market accounted for 22.7% of the global market, reaching USD 4.44 billion in 2025, and is projected to grow at a CAGR of 12.1% during the forecast period. Rising healthcare expenditure, increasing incidence of chronic diseases, expanding access to advanced imaging technologies, and growing investments in nuclear medicine infrastructure continue to accelerate regional market growth. Expanding radiopharmaceutical production capabilities further strengthen market expansion.
Japan's market generated USD 0.80 billion in 2025. Increasing demand for molecular imaging technologies, expanding applications of nuclear medicine in oncology, growing aging population, and continuous innovation in diagnostic imaging continue to support market growth.
China's market accounted for USD 1.86 billion in 2025, representing the largest share within Asia Pacific. Growing healthcare investments, expanding nuclear medicine facilities, increasing adoption of advanced diagnostic technologies, and rising demand for precision medicine continue to drive market expansion.
Latin America nuclear medicine market accounted for 5.1% of the global market, reaching USD 1.00 billion in 2025, and is projected to grow at a CAGR of 9.6% during the forecast period. Increasing healthcare investments, expanding access to diagnostic imaging services, rising demand for cancer diagnostics, and improving medical infrastructure continue to support regional market growth.
Brazil market accounted for USD 0.54 billion in 2025. Rising investments in healthcare modernization, increasing availability of radiopharmaceuticals, expanding diagnostic imaging capabilities, and growing awareness of precision diagnostics continue to support market expansion.
Middle East & Africa nuclear medicine market accounted for 3.2% of the global market, totaling USD 0.63 billion in 2025, and is projected to grow at a CAGR of 8.9% during the forecast period. Increasing investments in healthcare infrastructure, expanding adoption of advanced diagnostic technologies, improving access to nuclear medicine services, and rising prevalence of chronic diseases continue to support regional market growth.
The UAE market was valued at USD 0.15 billion in 2025. Expanding investments in specialized healthcare facilities, increasing adoption of advanced molecular imaging technologies, growing medical tourism, and rising demand for precision diagnostics continue to drive market growth.
Africa's market reached USD 0.48 billion in 2025. Improving healthcare infrastructure, increasing access to diagnostic imaging services, expanding government healthcare initiatives, and growing awareness of nuclear medicine applications continue to create long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Precision Cardiology Market Size, Share, Growth, Analysis, 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Latin America Neurodegenerative Diseases Market Includes Latest Trends, 2034
Asia Pacific Neurodegenerative Diseases Market Size, Share by 2034
LAMEA Lidocaine Market Size, Growth , 2026-2034
North America Neurodegenerative Disease Market Size, 2034
We are featured on:
sales@straitsresearch.com